Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it usually occurs following chronic liver disease. Although some progress has been made in the treatment of HCC, the prognosis of patients with advanced HCC is not optimistic, mainly because of the inevitable develop...
Saved in:
Main Authors: | Lei Jiang (Author), Luan Li (Author), Yongzhuang Liu (Author), Meixiao Zhan (Author), Ligong Lu (Author), Shengtao Yuan (Author), Yanyan Liu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
by: Frontiers Production Office
Published: (2023) -
Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis
by: Miaomiao Yang, et al.
Published: (2024) -
Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma
by: Yue Chen, et al.
Published: (2024) -
Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011) -
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015)